CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
World-Renowned Scientist and Co-founder of Moderna, Dr. Robert Langer, to Guide Sethera’s Scientific Strategy; Brigadier General Larry V. Lunt, USAF (Ret.), Adds Decades of Strategic Leadership Experience to Sethera’s Board
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
The partnership combines Tasso’s clinical grade blood collection solutions, such as the Tasso+ device pictured above, with ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research.